← Russell 3000 cross-section

ACRS Aclaris Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$914m
Revenue TTM
$8m
Net income TTM
$-76m
Free cash flow
$-62m
Composite score
29.5
Sector rank
#2062

Valuation

P / E
EV / EBITDA
EV / sales
100.1
FCF yield
-6.80%
Earnings yield vs 10-yr
-13.01pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-921.5%
EBITDA margin
-1,045.0%
ROE
-60.8%
ROIC
-261.4%
Revenue growth
-51.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The Warrants will terminate when exercised in full. ​ As of June 30, 2026, 3,000,000 Warrants were unexercised. ​ Sales of Common Stock Pursuant to At-The-Market Facility ​ In March 2026, the Company sold an aggregate of 18.4 million shares of its common stock for gross proceeds of $ 59.8 million, pursuant to an amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., as sales agents, dated February 27, 2025. …Aclaris Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →